Please wait while the formulary information is being retrieved.
DOXAPRAM HCL (DOXAPRAM HCL)
- Post-anesthesia respiratory depression
doxapram 20 mg/mL intravenous solution
- Dosage information is not available
20 mg/mL intravenous solution
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- Acute asthma attack
- Acute decompensated heart failure
- Cerebral edema
- Cerebrovascular accident
- Flail chest
- Hypoventilation
- Lower seizure threshold
- Neuromuscular blockade
- Pheochromocytoma
- Pneumothorax
- Pulmonary fibrosis
- Pulmonary thromboembolism
- Respiratory obstruction
- Seizure disorder
- Severe coronary artery disease
- Severe uncontrolled hypertension
Contraindicated
- Hyperthyroidism
- Hypotension
- Mechanical ventilation
Severe
Moderate
- Cardiac arrhythmia
- Disease of liver
- Kidney disease with reduction in GFR
- Leukopenia
DOXAPRAM HCL (DOXAPRAM HCL)
- Post-anesthesia respiratory depression
- None
- None
More Frequent
Severe
Less Severe
- None
- Acute confusion
- Cough
- Diarrhea
- Dizziness
- Dysuria
- Flushing
- Headache disorder
- Hiccups
- Hyperhidrosis
- Nausea
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Cardiac arrhythmia
- Chest pain
- Chest tightness
- Dyspnea
- Hemolysis
- Hypertension
- Tachycardia
- Tachypnea
- Thrombophlebitis
- Wheezing
Less Severe
- None
Contraindicated
None
Severe Precaution
Doxapram
Increased risk of adverse events in premature infants include hypertension, irritability, vomiting, abdominal distension, heart block. Additional risk of seizure in premature infants with underlying CNS condition (e.g. previous seizure, peri-natal asphyxia). Contains benzyl alcohol.
- 1 Day – 364 Days
- Increased risk of adverse events in premature infants include hypertension, irritability, vomiting, abdominal distension, heart block. Additional risk of seizure in premature infants with underlying CNS condition (e.g. previous seizure, peri-natal asphyxia). Contains benzyl alcohol.
Management or Monitoring Precaution
Doxapram
Safety and effectiveness not established age < 12 years.
- 1 Years – 12 Years
- Safety and effectiveness not established age < 12 years.
Doxapram Hydrochloride
- Severity Level:
B
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Doxapram
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Doxapram Hydrochloride
Assess risk-benefit in cardiac, hepatic, or renal impairment
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Post-anesthesia respiratory depression | |
| J95.1 | Acute pulmonary insufficiency following thoracic surgery |
| J95.2 | Acute pulmonary insufficiency following nonthoracic surgery |
| J95.82 | Postprocedural respiratory failure |
| J95.821 | Acute postprocedural respiratory failure |
| J95.822 | Acute and chronic postprocedural respiratory failure |
| 0-9 | A-Z |
|---|---|
| J95.1 | Acute pulmonary insufficiency following thoracic surgery |
| J95.2 | Acute pulmonary insufficiency following nonthoracic surgery |
| J95.82 | Postprocedural respiratory failure |
| J95.821 | Acute postprocedural respiratory failure |
| J95.822 | Acute and chronic postprocedural respiratory failure |
Formulary Reference Tool